Supplemental Material to:

Adverse Events Following SARS-CoV-2 mRNA Vaccination in Adolescents

A Norwegian Nationwide Register-Based Study

Vilde Bergstad Larsen¹, Nina Gunnes^{2,3}, Jon Michael Gran⁴, Jesper Dahl⁵, Håkon Bøås⁵, Sara Viksmoen Watle⁵, Jacob Dag Berild⁵, Margrethe Greve-Isdahl⁵, Ketil Størdal⁶, Hanne Løvdal Gulseth², Øystein Karlstad², Paz Lopez-Doriga Ruiz^{2,7}, German Tapia²

Corresponding author: German Tapia, Norwegian Institute of Public Health, Marcus Thranes gate 6, 0473 Oslo, Norway; german.tapia@fhi.no

¹Division for Health Services, Norwegian Institute of Public Health, Oslo, Norway

²Division of Mental and Physical Health, Norwegian Institute of Public Health, Oslo, Norway

³Norwegian Research Centre for Women's Health, Oslo University Hospital, Oslo, Norway

⁴Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Oslo, Norway

⁵Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway ⁶Department of Pediatric Research, Institute of Clinical Medicine, University of Oslo, and Oslo University Hospital, Oslo, Norway

⁷Institute of Community Health and Global Medicine, University of Oslo, Oslo, Norway

Contents

Supplementary Materials	3
Data Sources in Beredt C19	3
National Population Register	3
Norwegian Surveillance System for Communicable Diseases	3
Norwegian Immunisation Registry	3
Norwegian Registry of Primary Health Care	3
Norwegian Patient Registry	3
Norwegian Cause of Death Registry	3
Supplementary Table 1	5
Supplementary Table 2	8
Supplementary Table 3	11
Supplementary Table 4:	14
Supplementary Table 5:	17

Supplementary Materials

This section includes additional information about the current study.

Data Sources in Beredt C19

Beredt C19 was established in April 2020 by the Norwegian Institute of Public Health to monitor infections, vaccinations, and use of health services in Norway during the COVID-19 pandemic (https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19/). The register consists of historical and real-time data from various nationwide electronic health registers and administrative databases to which all reporting is mandatory, thereby covering the entire population in Norway. Data sources in Beredt C19 relevant for the current study are described below.

National Population Register

The National Population Register (https://www.skatteetaten.no/en/person/national-registry/) provided information on date and place of birth, sex, date of immigration, county of residence, date of emigration, date of death, and residential status (resident, emigrated, or deceased). The register is updated weekly in Beredt C19.

Norwegian Surveillance System for Communicable Diseases

Information on laboratory-confirmed SARS-CoV-2 infection dates was provided by the Norwegian Surveillance System for Communicable Diseases (MSIS), which is run by the Norwegian Institute of Public Health. All laboratories are legally required to report date of testing and test results to the MSIS. The register is updated daily in Beredt C19.

Norwegian Immunisation Registry

The Norwegian Immunisation Registry (SYSVAK) provided information on SARS-CoV-2 vaccination dates and vaccine types. SYSVAK is run by the Norwegian Institute of Health and updated daily in Beredt C19.

Norwegian Registry of Primary Health Care

The Norwegian Registry of Primary Health Care is based on government reimbursement claims from the primary health services in Norway, including publicly funded general practitioners and primary care emergency clinics. Diagnoses are coded using the International Classification of Primary Care, Second Edition (ICPC-2). The register is updated daily in Beredt C19. In the current study, it provided information on date of diagnosis of herpes zoster (ICPC-2 code S70).

Norwegian Patient Registry

The Norwegian Patient Registry (NPR) collects data from the specialist health services in Norway, which includes all government-owned hospitals and outpatient clinics. Diagnoses are coded using the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10). Reporting to the NPR forms the basis for government reimbursements to the specialist health services in Norway. Together with the Norwegian Registry of Primary Health Care, the NPR covers all government-funded health care in Norway. The register is updated daily in Beredt C19. It provided information on dates of all hospital admissions/discharges and outpatient visits and the corresponding diagnoses.

Norwegian Cause of Death Registry

Information on county of residence for deceased subjects was retrieved from the Norwegian Cause of Death Registry, as home address is deleted from the National Population Register upon death. We also used the Norwegian Cause of Death Registry to ascertain whether any subjects were registered

with vaccine-associated death (ICD-10 code U12.9). The register is run by the Norwegian Institute of Public Health and updated weekly in Beredt C19.

Supplementary Table 1: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 477,097 adolescents in Norway aged 12–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 and previously uninfected with SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination of their age group until the outcome in question, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, SARS-CoV-2 infection, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by "< 5". As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ²		Crude analys	is		Adjusted analysis³	
	willdow		Subjects	events	rate	IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	Overall	472,625	802	217.77						
		Unvaccinated (ref.)	471,868	184	184.88	1			1		
		Vaccinated with 1st dose, inside risk window	388,948	34	229.38	1.24	0.86-1.79	0.248	1.33	0.90-1.96	0.147
		Vaccinated with 1st dose, outside risk window	384,298	300	229.31	1.24	1.03-1.49	0.021	1.56	1.25-1.94	0.000
		Vaccinated with 2 nd dose, inside risk window	213,406	20	246.64	1.33	0.84 - 2.12	0.221	1.42	0.87-2.30	0.159
		Vaccinated with 2 nd dose, outside risk window	210,127	264	229.58	1.24	1.03-1.50	0.024	1.45	1.10-1.90	0.008
Anaphylactic reaction	2 days	Overall	476,333	41	11.04						
		Unvaccinated (ref.)	475,564	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,153	< 5	46.58	5.19	0.66-40.98	0.118	6.84	0.81-57.81	0.077
		Vaccinated with 1st dose, outside risk window	391,666	19	13.13	1.46	0.66-3.23	0.347	2.75	1.00-7.56	0.049
		Vaccinated with 2 nd dose, inside risk window	215,309	< 5	84.86	9.46	1.20-74.65	0.033	11.02	1.26-96.68	0.030
		Vaccinated with 2 nd dose, outside risk window	214,849	11	8.94	1.00	0.41-2.40	0.993	0.88	0.26-2.95	0.830
Arrhythmia	28 days	Overall	475,961	90	24.25						
		Unvaccinated (ref.)	475,194	26	25.94	1			1		
		Vaccinated with 1st dose, inside risk window	391,814	< 5	10.11	0.39	0.12-1.29	0.122	0.38	0.11-1.31	0.126
		Vaccinated with 1st dose, outside risk window	374,429	24	20.49	0.79	0.45-1.38	0.405	1.12	0.58-2.16	0.726
		Vaccinated with 2 nd dose, inside risk window	215,069	< 5	6.15	0.24	0.03-1.75	0.158	0.20	0.03-1.56	0.126
		Vaccinated with 2 nd dose, outside risk window	210,483	36	33.37	1.29	0.78-2.13	0.328	1.34	0.64-2.82	0.438
Arthropathy	42 days	Overall	476,515	0	0.00						
		Unvaccinated (ref.)	475,746	0	0.00	1			1		
		Vaccinated with 1st dose, inside risk window	392,319	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1st dose, outside risk window	336,587	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	215,425	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,863	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	Overall	476,409	22	5.92						
		Unvaccinated (ref.)	475,640	8	7.97	1			1		
		Vaccinated with 1st dose, inside risk window	392,224	< 5	10.10	1.27	0.34-4.77	0.727	1.26	0.28-5.58	0.764
		Vaccinated with 1st dose, outside risk window	374,812	7	5.97	0.75	0.27-2.07	0.577	0.88	0.26-2.98	0.838
		Vaccinated with 2 nd dose, inside risk window	215,353	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	210,758	< 5	3.70	0.46	0.14-1.54	0.210	0.27	0.06-1.28	0.100
Death	28 days	Overall	476,515	90	24.22						
	-	Unvaccinated (ref.)	475,746	36	35.87	1			1		
		Vaccinated with 1 st dose, inside risk window	392,319	7	23.56	0.66	0.29-1.48	0.309	0.71	0.29-1.69	0.433
		Vaccinated with 1 st dose, outside risk window	374,903	18	15.35	0.43	0.24-0.75	0.003	0.59	0.31-1.13	0.110
		Vaccinated with 2 nd dose, inside risk window	215,425	5	30.68	0.86	0.34-2.18	0.743	0.69	0.26-1.87	0.471
		Vaccinated with 2 nd dose, outside risk window	210,830	24	22.21	0.62	0.37-1.04	0.069	0.40	0.20-0.78	0.007
Encephalomyelitis and meningitis	28 days	Overall	476,453	7	1.88						
	•	Unvaccinated (ref.)	475,684	< 5	1.00	1			1		
		Vaccinated with 1 st dose, inside risk window	392,267	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	374,854	< 5	1.71	1.71	0.16-18.88	0.661	1.18	0.10-13.79	0.895
		Vaccinated with 2 nd dose, inside risk window	215,394	< 5	6.14	6.16	0.39-98.45	0.199	5.98	0.28-126.35	0.251
		Vaccinated with 2 nd dose, outside risk window	210,799	< 5	2.78	2.79	0.29-26.78	0.375	1.69	0.11-26.81	0.709
Epilepsy and convulsions	28 days	Overall	471,600	454	123.56						

		Unvaccinated (ref.)	470,838	107	107.85	1			1		
		Vaccinated with 1 st dose, inside risk window	388,243	29	98.63	0.91	0.61-1.38	0.670	1.07	0.69-1.67	0.749
		Vaccinated with 1 st dose, misde risk window	370,996	157	135.46	1.26	0.98-1.61	0.069	1.21	0.91-1.61	0.187
		Vaccinated with 2 nd dose, inside risk window	213,099	28	173.71	1.61	1.06-2.44	0.025	1.65	1.05-2.59	0.028
		Vaccinated with 2 nd dose, outside risk window	208,521	133	124.53	1.15	0.90-1.49	0.268	1.01	0.71-1.44	0.944
Facial nerve palsy	28 days	Overall	476,148	57	15.35	1.13	0.50 1.15	0.200	1.01	0.71 1.11	0.511
racial fierve parsy	20 days	Unvaccinated (ref.)	475,379	19	18.95	1			1		
		Vaccinated with 1 st dose, inside risk window	392,016	< 5	13.47	0.71	0.24-2.09	0.535	0.65	0.21-2.02	0.454
		Vaccinated with 1 st dose, misde risk window Vaccinated with 1st dose, outside risk window	374,613	10	8.54	0.45	0.21–0.97	0.041	0.47	0.20-1.11	0.085
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	215,248	< 5	12.28	0.65	0.15-2.78	0.560	0.49	0.11-2.26	0.359
		Vaccinated with 2 nd dose, outside risk window	210,657	22	20.38	1.08	0.58-1.99	0.816	1.02	0.41-2.53	0.964
Guillain-Barré syndrome	42 days	Overall	476,503	< 5	0.81	1.00	0.50 1.55	0.010	1.02	0.41 2.33	0.504
Guillain-Barre Syndrome	42 days	Unvaccinated (ref.)	475,734	0	0.00	1			1		
		Vaccinated with 1st dose, inside risk window	392,307	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 dose, inside risk window Vaccinated with 1st dose, outside risk window	336,577	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	215,416	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,855	< 5	3.00	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	Overall	476,444	7	1.88	ND	ND	NU	ND	ND	IND
rienoch-schoniem purpura	42 days	Unvaccinated (ref.)	475,675	< 5	1.00	1			1		
		Vaccinated with 1st dose, inside risk window	392,263	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 dose, inside risk window Vaccinated with 1st dose, outside risk window	336,538	5	4.84	4.85	0.57-41.52	0.149	ND	ND	ND
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	215,397	0	0.00	ND	0.57-41.52 ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	208,835	< 5	1.00	1.00	0.06-16.04	0.998	ND	ND	ND
Herpes zoster	28 days	Overall	476,297	47	12.65	1.00	0.00-10.04	0.336	IND	ND ND	ND_
nerpes zoster	20 uays	Unvaccinated (ref.)	475,528	9	8.97	1			1		
		Vaccinated with 1st dose, inside risk window	392,127	< 5	6.73	0.75	0.16-3.47	0.714	1.00	0.20-5.09	0.997
		Vaccinated with 1 dose, inside risk window Vaccinated with 1st dose, outside risk window	374,721	15	12.80	1.43	0.10-3.47	0.714	1.30	0.49-3.42	0.598
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	215,299	< 5	6.14	0.68	0.02-5.20	0.333	0.82	0.49-3.42	0.358
		Vaccinated with 2 dose, inside risk window Vaccinated with 2 nd dose, outside risk window	210,710	20	18.52	2.06	0.09-5.40	0.719	1.86	0.62-5.56	0.855
Idiopathic thrombocytopenic	28 days	Overall	476,398	18	4.84	2.00	0.34-4.33	0.071	1.00	0.02-3.30	0.203
• • • • • • • • • • • • • • • • • • • •	20 uays	Unvaccinated (ref.)	475,629	5	4.64	1			1		
purpura		Vaccinated with 1st dose, inside risk window	392,227	< 5	6.73	1.35	0.26-6.96	0.719	0.98	0.18-5.44	0.983
		Vaccinated with 1st dose, inside risk window Vaccinated with 1st dose, outside risk window		< 5 5	4.27	0.86	0.25-2.96	0.719	1.28	0.18-5.44	0.983
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	374,817	_						0.29-3.71	
		Vaccinated with 2 dose, inside risk window Vaccinated with 2 nd dose, outside risk window	215,372	< 5	6.14	1.23 0.93	0.14-10.54	0.849	1.16	0.37-12.99	0.901
Luna in ha dan a nathu	1.4 days	Overall	210,779	5	4.63	0.93	0.27-3.21	0.907	2.18	0.37-12.99	0.391
Lymphadenopathy	14 days		474,345	438	118.44	1			1		
		Unvaccinated (ref.)	473,581	97	97.10	1	0.60 1.70	0.002	1	0.70. 3.10	0.474
		Vaccinated with 1st dose, inside risk window	390,457	15	100.80	1.04	0.60-1.79	0.893	1.23	0.70-2.18	0.474
		Vaccinated with 1 st dose, outside risk window	385,807	157	119.52	1.23	0.96–1.59	0.108	1.29	0.96–1.73	0.094
		Vaccinated with 2 nd dose, inside risk window	214,303	20	245.61	2.53	1.56-4.09	0.000	2.73	1.63-4.58	0.000
NA. Itio vetore in flore monto m.	42 days	Vaccinated with 2 nd dose, outside risk window	211,014	149	128.98	1.33	1.03-1.72	0.030	1.40	0.98-2.01	0.068
Multisystem inflammatory	42 days	Overall	476,500	6	1.61	4			4		
syndrome in children		Unvaccinated (ref.)	475,731	< 5	1.00	1	0.14.36.03	0.555	1 1.64	0.00.30.30	0.744
		Vaccinated with 1 st dose, inside risk window	392,305	< 5	2.30	2.30	0.14-36.83	0.555	1.61	0.09-28.39	0.744
		Vaccinated with 1 st dose, outside risk window	336,576	< 5	1.93	1.94	0.18-21.41	0.588	3.26	0.11–93.03	0.490
		Vaccinated with 2 nd dose, inside risk window	215,420	0	0.00	ND	ND	ND 0.570	ND	ND	ND 0.400
NAME and this are discourt to the control of the co	20 4	Vaccinated with 2 nd dose, outside risk window	208,858	< 5	2.00	2.01	0.18-22.13	0.570	3.73	0.08-169.70	0.499
Myocarditis and pericarditis	28 days	Overall	476,463	< 53	13.73	4			4		
		Unvaccinated (ref.)	475,694	9	8.97	1	0.20 4.10	0.050	1	0.25 7.04	0.553
		Vaccinated with 1 st dose, inside risk window	392,268	< 5	10.10	1.13	0.30-4.16	0.859	1.57	0.35-7.04	0.557
		Vaccinated with 1 st dose, outside risk window	374,855	13	11.09	1.24	0.53-2.89	0.625	4.84	1.42-16.47	0.012

		Vaccinated with 2 nd dose, inside risk window	215,375	11	67.52	7.53	3.12-18.17	0.000	9.19	2.69-31.45	0.000
		Vaccinated with 2 nd dose, outside risk window	210,769	15	13.89	1.55	0.68-3.54	0.300	3.16	0.79-12.64	0.104
Venous thromboembolic events	28 days	Overall	476,415	< 54	14.00						
		Unvaccinated (ref.)	475,646	9	8.97	1			1		
		Vaccinated with 1 st dose, inside risk window	392,221	5	16.83	1.88	0.63-5.60	0.259	2.40	0.67-8.62	0.180
		Vaccinated with 1 st dose, outside risk window	374,811	13	11.09	1.24	0.53-2.89	0.625	2.67	0.85-8.41	0.094
		Vaccinated with 2 nd dose, inside risk window	215,335	< 5	18.42	2.05	0.56-7.58	0.281	2.17	0.48-9.73	0.313
		Vaccinated with 2 nd dose, outside risk window	210,737	22	20.37	2.27	1.05-4.93	0.038	2.53	0.72-8.85	0.147

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), attained age by the end of 2021 (12–15 years, 16–17 years, or 18–19 years), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 2: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 253,669 adolescents in Norway aged 12–15 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by "< 5". As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of	Number of	Incidence rate ²		Crude analysis	5		Adjusted analysis ³	
	window		subjects	events	rate	IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	Overall	251,681	< 539	200.50						
		Unvaccinated (ref.)	250,982	123	151.17	1			1		
		Vaccinated with 1st dose, inside risk window	188,097	18	249.69	1.65	1.01-2.71	0.047	1.91	1.12-3.27	0.017
		Vaccinated with 1 st dose, outside risk window	188,054	367	225.83	1.49	1.22-1.83	0.000	1.40	1.14-1.74	0.002
		Vaccinated with 2 nd dose, inside risk window	28,920	< 5	180.78	1.20	0.30-4.84	0.802	1.13	0.28-4.61	0.860
		Vaccinated with 2 nd dose, outside risk window	28,813	26	171.73	1.14	0.74-1.73	0.555	1.06	0.68-1.63	0.806
Anaphylactic reaction	2 days	Overall	253,579	21	7.79						
		Unvaccinated (ref.)	252,869	5	6.10	1			1		
		Vaccinated with 1st dose, inside risk window	189,544	< 5	96.35	15.81	1.85-135.31	0.012	16.19	1.29-202.98	0.031
		Vaccinated with 1st dose, outside risk window	189,535	13	7.64	1.25	0.45-3.52	0.668	1.16	0.40-3.38	0.779
		Vaccinated with 2 nd dose, inside risk window	29,154	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	29,124	< 5	12.32	2.02	0.39-10.42	0.401	1.35	0.25-7.30	0.731
Arrhythmia	28 days	Overall	253,474	49	18.18						
		Unvaccinated (ref.)	252,765	14	17.08	1			1		
		Vaccinated with 1st dose, inside risk window	189,459	< 5	6.89	0.40	0.05-3.07	0.380	0.31	0.04-2.40	0.261
		Vaccinated with 1st dose, outside risk window	189,193	29	18.52	1.08	0.57-2.05	0.803	1.26	0.62-2.55	0.528
		Vaccinated with 2 nd dose, inside risk window	29,146	< 5	44.94	2.63	0.35-20.01	0.350	3.75	0.47-30.02	0.213
		Vaccinated with 2 nd dose, outside risk window	28,909	< 5	28.25	1.65	0.54-5.03	0.374	1.89	0.57-6.22	0.294
Arthropathy	42 days	Overall	253,666	0	0.00						
		Unvaccinated (ref.)	252,956	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	189,617	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,147	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,843	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	Overall	253,630	< 15	5.19						
		Unvaccinated (ref.)	252,920	< 5	4.88	1			1		
		Vaccinated with 1 st dose, inside risk window	189,585	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,320	10	6.38	1.31	0.41-4.17	0.649	1.28	0.35-4.70	0.706
		Vaccinated with 2 nd dose, inside risk window	29,168	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,932	0	0.00	ND	ND	ND	ND	ND	ND
Death	28 days	Overall	253,666	32	11.86						
		Unvaccinated (ref.)	252,956	18	21.94	1			1		
		Vaccinated with 1 st dose, inside risk window	189,617	< 5	6.88	0.31	0.04-2.35	0.259	0.43	0.05-3.46	0.426
		Vaccinated with 1 st dose, outside risk window	189,352	12	7.66	0.35	0.17-0.72	0.005	0.31	0.15-0.66	0.002
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,940	< 5	7.05	0.32	0.04-2.41	0.269	0.22	0.03-1.66	0.140
Encephalomyelitis and meningitis	28 days	Overall	253,632	5	1.85						
	•	Unvaccinated (ref.)	252,922	< 5	2.44	1			1		
		Vaccinated with 1 st dose, inside risk window	189,592	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,327	< 5	1.91	0.78	0.13-4.70	0.791	0.71	0.12-4.27	0.708
		Vaccinated with 2 nd dose, inside risk window	29,169	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	0	0.00	ND	ND	ND	ND	ND	ND
Epilepsy and convulsions	28 days	Overall	251,005	< 301	111.34						

		I Investigated (ref.)	250 200	02	112.45	1			1		
		Unvaccinated (ref.)	250,300	92	113.45	1	0.67.1.92	0.702	1	0.75.2.10	0.269
		Vaccinated with 1 st dose, inside risk window	187,667	18	125.16	1.10	0.67–1.83	0.703	1.28	0.75-2.18	0.368
		Vaccinated with 1 st dose, outside risk window	187,388	170	109.62	0.97	0.75–1.25	0.790	0.91	0.70-1.18	0.467
		Vaccinated with 2 nd dose, inside risk window Vaccinated with 2 nd dose, outside risk window	28,818	< 5	45.45	0.40	0.06–2.87 0.59–1.72	0.363 0.975	0.33 0.92	0.05–2.37 0.53–1.58	0.269
Facial name nalar	20 days	Overall	28,583	16 37	114.43 13.73	1.01	0.59-1.72	0.975	0.92	0.55-1.56	0.751
Facial nerve palsy	28 days		253,469			1			1		
		Unvaccinated (ref.)	252,759	18	21.96	1	0.15.3.70	0.522	1	0.16.2.57	0.721
		Vaccinated with 1 st dose, inside risk window	189,480	< 5	13.77	0.63	0.15–2.70 0.20–0.82	0.532	0.76	0.16-3.57	0.731
		Vaccinated with 1 st dose, outside risk window Vaccinated with 2 nd dose, inside risk window	189,213	14	8.94	0.41 ND	0.20 - 0.82 ND	0.012	0.38	0.18-0.78	0.008
		Vaccinated with 2 nd dose, inside risk window Vaccinated with 2 nd dose, outside risk window	29,144	0	0.00	0.96		ND 0.054	ND	ND	ND 0.636
Cuillein Donné sun drance	42 days		28,908	< 5	21.19	0.96	0.28-3.28	0.954	0.73	0.21–2.59	0.626
Guillain-Barré syndrome	42 days	Overall	253,663	< 5	1.11	1			1		
		Unvaccinated (ref.)	252,953	0	0.00	1	ND	ND	1	ND	ND
		Vaccinated with 1 st dose, inside risk window	189,614	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,144	< 5	1.34	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,175	0	0.00	ND	ND	ND	ND	ND	ND
Harris California	42 4	Vaccinated with 2 nd dose, outside risk window	28,842	< 5	7.65	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	Overall	253,622	< 10	2.22	4			4		
		Unvaccinated (ref.)	252,912	< 5	1.22	1	ND	ND	1	ND	ND
		Vaccinated with 1 st dose, inside risk window	189,586	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,116	5	3.35	2.74	0.32–23.49	0.357	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	29,173	0	0.00	ND	ND	ND	ND	ND	ND
H	20 1	Vaccinated with 2 nd dose, outside risk window	28,840	0	0.00	ND	ND	ND	ND	ND	ND
Herpes zoster	28 days	Overall ()	253,556	< 44	14.84						
		Unvaccinated (ref.)	252,846	10	12.19	1	0.07.4.44	0.506	1	0.40.44.00	0.057
		Vaccinated with 1 st dose, inside risk window	189,529	< 5	6.88	0.56	0.07-4.41	0.586	1.23	0.13–11.20	0.857
		Vaccinated with 1 st dose, outside risk window	189,263	24	15.32	1.26	0.60–2.63	0.544	1.01	0.47–2.16	0.976
		Vaccinated with 2 nd dose, inside risk window	29,146	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,911	5	35.32	2.90	0.99–8.48	0.052	1.57	0.52-4.75	0.427
Idiopathic thrombocytopenic	28 days	Overall	253,601	13	4.82	_					
purpura		Unvaccinated (ref.)	252,891	< 5	3.66	1			1		
		Vaccinated with 1 st dose, inside risk window	189,572	< 5	13.77	3.76	0.63-22.51	0.147	3.06	0.42-22.09	0.267
		Vaccinated with 1 st dose, outside risk window	189,305	8	5.11	1.39	0.37–5.26	0.623	1.96	0.40–9.74	0.408
		Vaccinated with 2 nd dose, inside risk window	29,168	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	0	0.00	ND	ND	ND	ND	ND	ND
Lymphadenopathy	14 days	Overall	252,508	< 293	108.07						
		Unvaccinated (ref.)	251,803	74	90.65	1			1		
		Vaccinated with 1 st dose, inside risk window	188,737	6	82.95	0.92	0.40-2.10	0.834	1.12	0.47–2.69	0.798
		Vaccinated with 1 st dose, outside risk window	188,706	185	113.37	1.25	0.96–1.64	0.104	1.15	0.87–1.52	0.338
		Vaccinated with 2 nd dose, inside risk window	28,993	< 5	180.34	1.99	0.49-8.10	0.337	1.65	0.40–6.78	0.487
		Vaccinated with 2 nd dose, outside risk window	28,885	23	151.57	1.67	1.05-2.67	0.031	1.53	0.94–2.48	0.087
Multisystem inflammatory	42 days	Overall	253,650	12	4.45						
syndrome in children		Unvaccinated (ref.)	252,940	5	6.09	1			1		
		Vaccinated with 1 st dose, inside risk window	189,607	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,137	7	4.68	0.77	0.24-2.42	0.652	1.16	0.29-4.55	0.834
		Vaccinated with 2 nd dose, inside risk window	29,176	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,843	0	0.00	ND	ND	ND	ND	ND	ND
Myocarditis and pericarditis	28 days	Overall	253,659	10	3.71						
		Unvaccinated (ref.)	252,949	< 5	3.66	1			1		
		Vaccinated with 1 st dose, inside risk window	189,611	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,346	5	3.19	0.87	0.21 - 3.65	0.852	1.30	0.25-6.75	0.757

		Vaccinated with 2 nd dose, inside risk window	29,174	< 5	44.89	12.27	1.28-117.98	0.030	37.07	2.79-492.94	0.006
		Vaccinated with 2 nd dose, outside risk window	28,937	< 5	7.06	1.93	0.20-18.54	0.569	4.12	0.31-54.93	0.285
Venous thromboembolic events	28 days	Overall	253,650	16	5.93						
		Unvaccinated (ref.)	252,940	< 5	2.44	1			1		
		Vaccinated with 1 st dose, inside risk window	189,604	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	189,339	13	8.29	3.41	0.77-15.10	0.107	6.03	0.78-46.37	0.084
		Vaccinated with 2 nd dose, inside risk window	29,169	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	28,933	< 5	7.06	2.90	0.26-31.96	0.385	8.94	0.52-154.10	0.131

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 3: Crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 121,179 adolescents in Norway aged 16–17 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by "< 5". As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of subjects	Number of events	Incidence rate ² –		Crude analysis			Adjusted analysis ³	
						IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	Overall	120,117	300	227.97						
		Unvaccinated (ref.)	120,049	26	122.19	1			1		
		Vaccinated with 1 st dose, inside risk window	106,881	7	170.88	1.40	0.61-3.22	0.431	1.07	0.45-2.56	0.878
		Vaccinated with 1 st dose, outside risk window	106,863	81	261.83	2.14	1.38-3.33	0.001	2.38	1.50-3.77	0.000
		Vaccinated with 2 nd dose, inside risk window	91,662	10	284.68	2.33	1.12-4.83	0.023	2.81	1.30-6.09	0.009
		Vaccinated with 2 nd dose, outside risk window	91,618	176	245.22	2.01	1.33-3.03	0.001	2.19	1.38-3.48	0.001
Anaphylactic reaction	2 days	Overall	121,129	< 17	10.54						
		Unvaccinated (ref.)	121,060	< 5	9.32	1			1		
		Vaccinated with 1 st dose, inside risk window	107,798	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	107,796	5	14.37	1.54	0.30-7.96	0.604	1.79	0.34-9.43	0.495
		Vaccinated with 2 nd dose, inside risk window	92,475	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,474	7	9.27	0.99	0.21-4.79	0.995	0.82	0.15-4.55	0.823
Arrhythmia	28 days	Overall	121,024	< 36	24.11						
•	•	Unvaccinated (ref.)	120,956	6	27.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,700	< 5	12.13	0.43	0.05-3.60	0.438	0.33	0.04-2.98	0.324
		Vaccinated with 1 st dose, outside risk window	106,724	6	22.15	0.79	0.26-2.45	0.685	1.23	0.32-4.66	0.763
		Vaccinated with 2 nd dose, inside risk window	92,396	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,318	19	27.59	0.99	0.39-2.47	0.976	1.63	0.47-5.64	0.437
Arthropathy	42 days	Overall	121,179	0	0.00						
. ,	,	Unvaccinated (ref.)	121,110	0	0.00	1			1		
		Vaccinated with 1 st dose, inside risk window	107,846	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,676	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,518	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,393	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	Overall	121,144	11	8.28						
		Unvaccinated (ref.)	121,075	< 5	9.32	1			1		
		Vaccinated with 1st dose, inside risk window	107,818	< 5	36.34	3.90	0.65-23.33	0.136	5.52	0.71-42.97	0.102
		Vaccinated with 1 st dose, outside risk window	106,839	< 5	7.37	0.79	0.11-5.61	0.815	0.61	0.08-4.51	0.630
		Vaccinated with 2 nd dose, inside risk window	92,488	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,410	< 5	5.80	0.62	0.11-3.40	0.584	0.56	0.09-3.56	0.542
Death	28 days	Overall	121,179	< 31	21.82	0.02	0.11 5.10	0.301	0.50	0.03 3.30	0.5 12
Scatti	20 day3	Unvaccinated (ref.)	121,110	5	23.29	1			1		
		Vaccinated with 1 st dose, inside risk window	107,846	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	106,869	8	29.48	1.27	0.41-3.87	0.679	1.20	0.33-4.31	0.778
		Vaccinated with 1 dose, justified risk window	92,518	< 5	42.31	1.82	0.43-7.60	0.414	1.42	0.28-7.17	0.668
		Vaccinated with 2 nd dose, outside risk window	92,440	13	18.85	0.81	0.29–2.27	0.687	1.16	0.32-4.23	0.818
Encephalomyelitis and meningitis	28 days	Overall		< 5	1.50	0.81	0.23-2.27	0.087	1.10	0.32-4.23	0.010
incephalomyenus and meningitis	20 uays	Unvaccinated (ref.)	121,166	< 5 < 5	4.66	1			1		
		Vaccinated (ref.) Vaccinated with 1 st dose, inside risk window	121,097			1 ND	ND	ND	1 ND	ND	ND
		•	107,834	0	0.00 3.69	ND 0.79	0.05-12.64	ND 0.868	0.60	0.04–10.25	กบ 0.726
		Vaccinated with 1 st dose, outside risk window	106,858	< 5							
		Vaccinated with 200 dass inside risk window	02 500	^	0.00	KII 3		NID.	NID.	NID.	
		Vaccinated with 2 nd dose, inside risk window Vaccinated with 2 nd dose, outside risk window	92,508 92,431	0	0.00 0.00	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND

		Unvaccinated (ref.)	119,891	26	122.46	1			1		
		Vaccinated (iei.) Vaccinated with 1st dose, inside risk window	106,752	6	73.40	0.60	0.25-1.46	0.258	0.62	0.24-1.61	0.326
		Vaccinated with 1 dose, inside risk window Vaccinated with 1st dose, outside risk window	105,783	34	126.69	1.03	0.62-1.72	0.238	0.02	0.53-1.60	0.320
		Vaccinated with 1 dose, outside risk window Vaccinated with 2 nd dose, inside risk window	91,573	15	213.77	1.75	0.92-3.30	0.086	1.36	0.68-2.73	0.766
		Vaccinated with 2 nd dose, outside risk window	91,482	84	123.77	1.73	0.65-1.56	0.080	1.00	0.60-1.67	0.383
Facial nerve palsy	28 days	Overall	121,078	28	21.09	1.01	0.05-1.50	0.381	1.00	0.00-1.07	0.337
racial fierve paisy	Zo uays	Unvaccinated (ref.)	121,078	20 5	23.31	1			1		
		• •			12.12	1 0.52	0.06-4.45	0.550	1 0.26	0.03-2.29	0.225
		Vaccinated with 1 st dose, inside risk window	107,751	< 5				0.550			
		Vaccinated with 1 st dose, outside risk window	106,775	6	22.14	0.95	0.29-3.11	0.932	1.86	0.39-8.79	0.432
		Vaccinated with 2 nd dose, inside risk window	92,437	< 5	28.23 20.32	1.21 0.87	0.23–6.24 0.31–2.42	0.819 0.792	2.07	0.28–15.52	0.480
Cuillain Danné ann deann	42 dave	Vaccinated with 2 nd dose, outside risk window	92,357	14		0.87	0.31-2.42	0.792	3.15	0.62–16.12	0.168
Guillain-Barré syndrome	42 days	Overall	121,172	< 5	1.50				4		
		Unvaccinated (ref.)	121,103	0	0.00	1	ND	ND	1	ND	ND
		Vaccinated with 1 st dose, inside risk window	107,839	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,669	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,512	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,387	< 5	3.06	ND	ND	ND	ND	ND	ND
Henoch-Schönlein purpura	42 days	Overall	121,166	6	4.51						
		Unvaccinated (ref.)	121,097	< 5	4.66	1			1		
		Vaccinated with 1 st dose, inside risk window	107,832	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	105,662	< 5	8.67	1.86	0.17-20.53	0.612	1.12	0.10-12.83	0.926
		Vaccinated with 2 nd dose, inside risk window	92,504	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,379	< 5	4.59	0.98	0.10-9.46	0.989	0.78	0.06-9.44	0.843
Herpes zoster	28 days	Overall	121,117	21	15.81						
		Unvaccinated (ref.)	121,048	< 5	13.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,792	< 5	12.12	0.87	0.09-8.34	0.901	2.72	0.14-52.29	0.507
		Vaccinated with 1 st dose, outside risk window	106,815	< 5	7.38	0.53	0.09-3.16	0.484	0.57	0.09-3.47	0.542
		Vaccinated with 2 nd dose, inside risk window	92,476	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,398	15	21.76	1.56	0.45-5.38	0.484	0.68	0.19-2.41	0.545
Idiopathic thrombocytopenic	28 days	Overall	121,150	< 5	2.26						
purpura		Unvaccinated (ref.)	121,081	0	0.00	1			1		
		Vaccinated with 1st dose, inside risk window	107,824	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1st dose, outside risk window	106,848	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	92,501	< 5	14.11	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,422	< 5	2.90	ND	ND	ND	ND	ND	ND
Lymphadenopathy	14 days	Overall	120,635	< 181	135.37						
		Unvaccinated (ref.)	120,566	26	121.68	1			1		
		Vaccinated with 1st dose, inside risk window	107,344	< 5	72.92	0.60	0.18-1.98	0.401	0.70	0.20-2.50	0.587
		Vaccinated with 1st dose, outside risk window	107,330	49	157.61	1.30	0.81-2.08	0.286	1.16	0.71-1.91	0.548
		Vaccinated with 2 nd dose, inside risk window	92,070	10	283.42	2.33	1.12-4.83	0.023	1.90	0.87-4.13	0.105
		Vaccinated with 2 nd dose, outside risk window	92,026	91	126.16	1.04	0.67-1.60	0.871	0.95	0.58-1.54	0.825
Multisystem inflammatory	42 days	Overall	121,176	8	6.02						
syndrome in children	•	Unvaccinated (ref.)	121,107	< 5	4.66	1			1		
		Vaccinated with 1 st dose, inside risk window	107,843	< 5	24.33	5.22	0.54-50.23	0.152	5.99	0.48-75.25	0.166
		Vaccinated with 1 st dose, outside risk window	105,670	< 5	4.34	0.93	0.06-14.89	0.960	0.74	0.05-12.22	0.836
		Vaccinated with 2 nd dose, inside risk window	92,516	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	92,391	< 5	4.58	0.98	0.10-9.47	0.989	0.95	0.08-12.00	0.968
Myocarditis and pericarditis	28 days	Overall	121,169	18	13.54						
,	, -	Unvaccinated (ref.)	121,100	< 5	9.32	1			1		
		Vaccinated with 1 st dose, inside risk window	107,839	< 5	12.11	1.30	0.12-14.33	0.831	1.54	0.11-20.77	0.746
		Vaccinated with 1 st dose, outside risk window	106,861	7	25.80	2.77	0.58-13.33	0.204	2.15	0.41–11.17	0.362
		Tatomatea min 1 aose, outside fisit WilliadW	100,001	•	25.00	,,	0.50 15.55	0.207	2.13	V. 11 11.1/	- 3.302

		Vaccinated with 2 nd dose, inside risk window	92,509	< 5	14.11	1.51	0.14-16.69	0.735	1.00	0.08-12.12	1.000
		Vaccinated with 2 nd dose, outside risk window	92,430	7	10.15	1.09	0.23-5.24	0.915	1.43	0.25-8.33	0.688
Venous thromboembolic events	28 days	Overall	121,147	27	20.32						
		Unvaccinated (ref.)	121,078	< 5	13.98	1			1		
		Vaccinated with 1 st dose, inside risk window	107,816	< 5	24.23	1.73	0.29-10.37	0.547	1.39	0.19-10.44	0.748
		Vaccinated with 1 st dose, outside risk window	106,837	5	18.43	1.32	0.32-5.52	0.705	1.51	0.31-7.41	0.609
		Vaccinated with 2 nd dose, inside risk window	92,488	< 5	14.11	1.01	0.10-9.70	0.994	1.31	0.11-15.54	0.829
		Vaccinated with 2 nd dose, outside risk window	92,409	16	23.21	1.66	0.48-5.70	0.421	1.36	0.31-5.94	0.679

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 4: crude and adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on Poisson regression of 121,584 adolescents in Norway aged 18–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up. Subjects were followed from the beginning of the wave of vaccination, non-mRNA SARS-CoV-2 vaccination, third-dose SARS-CoV-2 vaccination, emigration, death, or end of study on September 30, 2022, whichever occurred first. To ensure data privacy, numbers between 1 and 4 have been suppressed and are denoted by "< 5". As a result, some of the totals have been suppressed as well to avoid revealing small numbers that have been suppressed.

Outcome	Risk window	Vaccination status	Number of	Number of	Incidence rate ²		Crude analysis			Adjusted analysis ³	
	window		subjects	events	rate	IRR	95% CI	P value	IRR	95% CI	P value
Acute appendicitis	14 days	Overall	120,562	349	250.73						
		Unvaccinated (ref.)	120,558	118	267.23	1			1		
		Vaccinated with 1 st dose, inside risk window	110,711	11	259.25	0.97	0.52-1.80	0.923	0.94	0.49-1.81	0.859
		Vaccinated with 1 st dose, outside risk window	110,671	47	273.35	1.02	0.73-1.43	0.895	1.09	0.72 - 1.64	0.696
		Vaccinated with 2 nd dose, inside risk window	104,941	9	223.78	0.84	0.43-1.65	0.608	0.83	0.40 - 1.71	0.607
		Vaccinated with 2 nd dose, outside risk window	104,910	164	235.70	0.88	0.70-1.12	0.298	1.02	0.71-1.46	0.929
Anaphylactic reaction	2 days	Overall	121,518	< 25	14.94						
		Unvaccinated (ref.)	121,514	5	11.23	1			1		
		Vaccinated with 1 st dose, inside risk window	111,693	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1st dose, outside risk window	111,690	8	38.05	3.39	1.11-10.36	0.032	8.49	1.91-37.66	0.005
		Vaccinated with 2 nd dose, inside risk window	105,912	< 5	172.43	15.36	1.79–131.46	0.013	38.78	3.46 - 434.39	0.003
		Vaccinated with 2 nd dose, outside risk window	105,909	7	9.49	0.84	0.27-2.66	0.774	2.10	0.37-12.07	0.406
Arrhythmia	28 days	Overall	121,337	< 57	38.49						
		Unvaccinated (ref.)	121,333	19	42.73	1			1		
		Vaccinated with 1 st dose, inside risk window	111,517	< 5	23.55	0.55	0.13-2.37	0.422	0.52	0.11-2.50	0.418
		Vaccinated with 1st dose, outside risk window	101,548	8	61.02	1.43	0.63-3.26	0.398	1.06	0.42 - 2.66	0.907
		Vaccinated with 2 nd dose, inside risk window	105,749	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,684	25	37.80	0.88	0.49-1.61	0.687	0.58	0.27-1.26	0.169
Arthropathy	42 days	Overall	121,569	0	0.00						
		Unvaccinated (ref.)	121,565	0	0.00	1			1		
		Vaccinated with 1st dose, inside risk window	111,743	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1st dose, outside risk window	67,275	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,968	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,857	0	0.00	ND	ND	ND	ND	ND	ND
Cerebrovascular events	28 days	Overall	121,533	6	4.27						
		Unvaccinated (ref.)	121,529	< 5	8.98	1			1		
		Vaccinated with 1st dose, inside risk window	111,706	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	101,722	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	105,931	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	105,866	< 5	3.02	0.34	0.06-1.84	0.208	1.06	0.06-19.60	0.971
Death	28 days	Overall	121,569	48	34.14						
		Unvaccinated (ref.)	121,565	18	40.41	1			1		
		Vaccinated with 1st dose, inside risk window	111,743	6	70.52	1.75	0.69-4.40	0.237	1.53	0.52-4.50	0.439
		Vaccinated with 1 st dose, outside risk window	101,754	< 5	22.84	0.57	0.17-1.92	0.360	0.70	0.18 - 2.73	0.610
		Vaccinated with 2 nd dose, inside risk window	105,968	< 5	24.63	0.61	0.14-2.63	0.507	0.59	0.12-2.92	0.521
		Vaccinated with 2 nd dose, outside risk window	105,903	19	28.67	0.71	0.37-1.35	0.297	1.30	0.46-3.66	0.623
Encephalomyelitis and meningitis	28 days	Overall	121,551	7	4.98						
	•	Unvaccinated (ref.)	121,547	< 5	2.25	1			1		
		Vaccinated with 1 st dose, inside risk window	111,727	0	0.00	ND	ND	ND	ND	ND	ND
		Vaccinated with 1st dose, outside risk window	101,739	< 5	7.61	3.39	0.21-54.23	0.388	1.43	0.09-22.99	0.799
		Vaccinated with 2 nd dose, inside risk window	105,952	< 5	12.32	5.48	0.34-87.69	0.229	4.67	0.22– 100.73	0.325

Pelepsy and convolvions			Vaccinated with 2 nd dose, outside risk window	105,886	< 5	6.04	2.69	0.30-24.06	0.376	0.80	0.09-7.48	0.846
Vescrianted with 1	Epilepsy and convulsions	28 days	Overall	120,364	155	111.40						
Machine Mach			Unvaccinated (ref.)	120,360	47	106.53	1			1		
			Vaccinated with 1st dose, inside risk window	110,582	5	59.38	0.56	0.22-1.40	0.214	0.73	0.27-1.98	0.538
Pacial nerve pally Pacia nerve			the contract of the contract o	100,711	21	161.49	1.52	0.91-2.54	0.113	1.85	0.97-3.54	0.064
Paralle nerve pally			Vaccinated with 2 nd dose, inside risk window	104,852	14	174.23	1.64	0.90-2.97	0.106	2.20	1.05-4.61	0.036
Direct cine Fig. Universimate Fig. Universimate Fig. Universimate Fig. Universimate Fig. Universimate Vis.			Vaccinated with 2 nd dose, outside risk window	104,776	68	103.72	0.97	0.67-1.41	0.888	1.08	0.60-1.93	0.806
Secondard with \$\begin{center}{cccccccccccccccccccccccccccccccccccc	Facial nerve palsy	28 days	Overall	121,480	< 30	18.51						
No.			Unvaccinated (ref.)	121,476	11	24.71	1			1		
Maciniaria with 1° dose, inside risk window 105,888 0			Vaccinated with 1 st dose, inside risk window	111,654	< 5	11.76	0.48	0.06-3.69	0.478	0.70	0.07-6.96	0.762
Maciniaria with 1° dose, inside risk window 105,888 0			Vaccinated with 1st dose, outside risk window	101,671	0	0.00	ND	ND	ND	ND	ND	ND
Machina					0	0.00	ND	ND	ND	ND	ND	ND
Membra			·		14	21.14	0.86	0.39-1.88	0.699	0.48	0.16-1.40	0.180
Machine Mach	Guillain-Barré syndrome	42 davs										
Machinate Mach		,.					1			1		
Machinate Mach			, ,					ND	ND	ND	ND	ND
												ND
No.			•									ND
Henoch-Schönlein purpura 42 days			·		_							ND
Marcinated (ref.) 121,551 0 0.00 1 1 1 1 1 1 1 1 1	Henoch-Schönlein nurnura	42 days					110	110	110	110	110	110
Vaccinated with 1	richoch Schomen parpara	42 days					1			1		
Vaccinated with \(^1\) dose, outside risk window \(^1\) (57.70 \(^1\) (0 \(^1\) (00 \(• •					ND	ND	ND	ND	ND
Marcinated with 1" dose, inside risk window vaccinated with 2" dose, outside risk window vaccinated with 2" d			·		•							ND
Merpes zoster			-									ND
Purpura Purp			·		_							ND
Unvaccinated (ref.) 121,504 5 11,23 1 1 1 1 1 1 1 1 1	Hornos zostor	29 days	•				ND	IND	ND	ND	ND	NU
No	nerpes zoster	20 uays					1			1		
Vaccinated with 1st dose, outside risk window 101,697 <5 22.85 2.04 0.49-8.52 0.33 1.70 0.31-9.34 0.31-9.3			• •					ND	ND		ND	ND
Multisystem inflammatory 42 days Vaccinated with 2 nd dose, inside risk window 105,908 05,9			•									
Multisystem inflammatory 42 days Multisystem inflammatory Multisystem in flammatory Mul			•									0.544
Idiopathic thrombocytopenic purpura 28 days Overall 121,538 121,53			•									0.942
Dury Dury Dury Dury Dury Dury Dury Dury	Library Harris Harris Harris Harris	20.4-					1.35	0.45-3.94	0.588	0.88	0.19-3.98	0.868
Vaccinated with 1st dose, inside risk window 111,711 0 0.00 ND ND ND ND ND ND ND	• • •	28 days					4			4		
Vaccinated with 1st dose, outside risk window 101,728 0 0.00 ND ND ND ND ND ND ND	purpura		,	•			1	*15	*15	1		
Vaccinated with 2 nd dose, inside risk window 105,936 0 0.00 ND ND ND ND ND ND ND			•		_							ND
Vaccinated with 2nd dose, outside risk window 105,872 5 7.55 1.12 0.27-4.69 0.877 2.45 0.39-15.45			-		_							ND
Lymphadenopathy			·		_							ND
Unvaccinated (ref.) 120,991 52 117.29 1 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.			·				1.12	0.27-4.69	0.877	2.45	0.39–15.45	0.340
Vaccinated with 1st dose, inside risk window 111,165 6 140.83 1.20 0.52–2.80 0.671 1.30 0.53–3.16 Vaccinated with 1st dose, outside risk window 111,130 15 86.87 0.74 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64 0.43–1.64 0.42–1.32 0.306 0.84 0.43–1.64	Lymphadenopathy	14 days										
Vaccinated with 1st dose, outside risk window 111,130 15 86.87 0.74 0.42—1.32 0.306 0.84 0.43—1.64 Vaccinated with 2nd dose, inside risk window 105,405 10 247.56 2.11 1.07—4.15 0.031 2.37 1.09—5.15 Vaccinated with 2nd dose, outside risk window 105,373 99 141.57 1.21 0.86—1.69 0.272 1.30 0.77—2.20 Multisystem inflammatory 42 days Overall 121,563 <5 0.71 Syndrome in children 121,563 <5 0.71 Vaccinated with 1st dose, inside risk window 111,737 0 0.00 ND ND ND ND ND Vaccinated with 1st dose, outside risk window 67,272 0 0.00 ND ND ND ND ND ND Vaccinated with 2nd dose, inside risk window 105,964 0 0.00 ND ND ND ND ND ND ND Vaccinated with 2nd dose, outside risk window 105,853 <5 1.61 ND ND ND ND ND ND ND N			• •									
Vaccinated with 2 nd dose, inside risk window 105,405 10 247.56 2.11 1.07–4.15 0.031 2.37 1.09–5.15 Vaccinated with 2 nd dose, outside risk window 105,373 99 141.57 1.21 0.86–1.69 0.272 1.30 0.77–2.20			-									0.568
Multisystem inflammatory syndrome in children 42 days Vaccinated with 2 nd dose, outside risk window 105,373 99 141.57 1.21 0.86–1.69 0.272 1.30 0.77–2.20 Multisystem inflammatory syndrome in children 42 days Overall 121,563 < 5			,									0.610
Multisystem inflammatory 42 days Overall syndrome in children Unvaccinated (ref.) Vaccinated with 1st dose, inside risk window 111,737 0 0.00 ND			·									0.030
syndrome in children Unvaccinated (ref.) 121,559 0 0.00 1 1 1 1 1 Vaccinated with 1st dose, inside risk window 111,737 0 0.00 ND			•	105,373	99	141.57	1.21	0.86–1.69	0.272	1.30	0.77–2.20	0.330
Vaccinated with 1^{st} dose, inside risk window 111,737 0 0.00 ND ND ND ND ND ND ND Vaccinated with 1^{st} dose, outside risk window 67,272 0 0.00 ND ND ND ND ND ND ND Vaccinated with 2^{nd} dose, inside risk window 105,964 0 0.00 ND	•	42 days	Overall		< 5							
Vaccinated with 1^{st} dose, outside risk window $67,272$ 0 0.00 ND ND ND ND ND ND ND Vaccinated with 2^{nd} dose, inside risk window $105,964$ 0 0.00 ND	syndrome in children		Unvaccinated (ref.)	121,559	0							
Vaccinated with 2^{nd} dose, inside risk window 105,964 0 0.00 ND			· · · · · · · · · · · · · · · · · · ·	111,737	0	0.00	ND	ND	ND	ND	ND	ND
Vaccinated with 2^{nd} dose, outside risk window 105,853 < 5 1.61 ND ND ND ND ND			Vaccinated with 1st dose, outside risk window	67,272	0	0.00	ND	ND	ND	ND	ND	ND
			Vaccinated with 2 nd dose, inside risk window	105,964	0	0.00	ND	ND	ND	ND	ND	ND
Myocarditis and pericarditis 28 days Overall 121 521 < 41 27 04			Vaccinated with 2 nd dose, outside risk window	105,853	< 5	1.61	ND	ND	ND	ND	ND	ND
171,001 and pencaratus 20 days Overall 121,001 \ \41 \ \21.04	Myocarditis and pericarditis	28 days	Overall	121,531	< 41	27.04						
Unvaccinated (ref.) 121,527 8 17.96 1 1	·	-	Unvaccinated (ref.)			17.96	1			1		

		Vaccinated with 1 st dose, inside risk window	111,700	< 5	23.51	1.31	0.28-6.16	0.733	1.87	0.31-11.29	0.493
		Vaccinated with 1st dose, outside risk window	101,714	5	38.10	2.12	0.69-6.48	0.187	3.91	0.81-18.77	0.089
		Vaccinated with 2 nd dose, inside risk window	105,926	9	110.87	6.17	2.38-16.00	< 0.001	10.25	2.36-44.47	0.002
		Vaccinated with 2 nd dose, outside risk window	105,852	14	21.14	1.18	0.49-2.81	0.713	2.84	0.61-13.15	0.182
Venous thromboembolic events	28 days	Overall	121,513	26	18.50						
		Unvaccinated (ref.)	121,509	6	13.47	1			1		
		Vaccinated with 1st dose, inside risk window	111,684	< 5	35.28	2.62	0.65-10.47	0.173	5.07	0.96-26.81	0.056
		Vaccinated with 1st dose, outside risk window	101,699	< 5	15.23	1.13	0.23-5.60	0.881	2.39	0.31-18.51	0.403
		Vaccinated with 2 nd dose, inside risk window	105,907	< 5	24.64	1.83	0.37-9.06	0.460	3.99	0.52-30.36	0.181
		Vaccinated with 2 nd dose, outside risk window	105,840	13	19.63	1.46	0.55-3.83	0.446	2.59	0.43-15.41	0.296

¹12–15-year-olds: September 6, 2021; 16–17-year-olds: August 23, 2021; 18–19-year-olds: April 5, 2021

²Per 100,000 person-years

³Adjustment for sex (male or female), health region (North Norway, Central Norway, West Norway, or South-East Norway), and risk group (no or yes) as baseline covariates and three-month calendar period (April–June 2021, July–September 2021, October–December 2021, January–March 2022, April–June 2022, and July–September 2022) as a time-varying covariate

Supplementary Table 5: Adjusted incidence rate ratios of 17 different outcomes between vaccinated and unvaccinated subjects, with associated 95% confidence intervals, based on self-controlled case series (SCCS) analysis of adolescents in Norway aged 12–19 years at the end of 2021 and unvaccinated against SARS-CoV-2 at the beginning of follow-up.

Outcome	Risk window	Va scination status	Number of	Adjusted analysis ¹			
		Vaccination status	events	IRR	95% CI	P value	
Acute appendicitis	14 days	Total	1,185				
		Unvaccinated (ref.)	267	1			
		Vaccinated with 1st dose, inside risk window	36	1.05	0.72-1.54	0.79	
		Vaccinated with 1st dose, outside risk window	495	1.15	0.90-1.45	0.26	
		Vaccinated with 2 nd dose, inside risk window	21	1.02	0.64-1.63	0.94	
		Vaccinated with 2 nd dose, outside risk window	366	0.97	0.78-1.22	0.81	
Anaphylactic reaction	2 days	Total	< 61				
		Unvaccinated (ref.)	12	1			
		Vaccinated with 1 st dose, inside risk window	< 5	4.92	0.59-41.11	0.14	
		Vaccinated with 1 st dose, outside risk window	26	2.02	0.74-5.49	0.17	
		Vaccinated with 2 nd dose, inside risk window	< 5	2.02	0.89-64.17	0.06	
		Vaccinated with 2 nd dose, outside risk window	16	0.77	0.29-2.03	0.60	
Arrhythmia	28 days	Total	135				
		Unvaccinated (ref.)	39	1			
		Vaccinated with 1st dose, inside risk window	< 5	0.48	0.16-1.41	0.18	
		Vaccinated with 1 st dose, outside risk window	43	1.01	0.53-1.91	0.99	
		Vaccinated with 2 nd dose, inside risk window	< 5	0.19	0.03-1.45	0.11	
		Vaccinated with 2 nd dose, outside risk window	48	1.30	0.71-2.39	0.39	
Arthropathy	42 days	Total	0				
	-	Unvaccinated (ref.)	0	1			
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND	
		Vaccinated with 1 st dose, outside risk window	0	ND	ND	ND	
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND	
		Vaccinated with 2 nd dose, outside risk window	0	ND	ND	ND	
Cerebrovascular events	28 days	Total	< 33				
	,	Unvaccinated (ref.)	10	1			
		Vaccinated with 1 st dose, inside risk window	< 5	1.22	0.26-5.72	0.80	

		Vaccinated with 1 st dose, outside risk window	12	0.80	0.22-2.92	0.74
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	6	0.44	0.11-1.75	0.24
Death	28 days	Total				
		Unvaccinated (ref.)		1		
		Vaccinated with 1 st dose, inside risk window		ND	ND	ND
		Vaccinated with 1 st dose, outside risk window		ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window		ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window		ND	ND	ND
Encephalomyelitis and meningitis	28 days	Total	14			
		Unvaccinated (ref.)	< 5	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	5	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	< 5	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	< 5	ND	ND	ND
Epilepsy and convulsions	28 days	Total	617			
		Unvaccinated (ref.)	165	1		
		Vaccinated with 1st dose, inside risk window	29	0.95	0.59-1.52	0.83
		Vaccinated with 1st dose, outside risk window	225	1.08	0.76-1.56	0.66
		Vaccinated with 2 nd dose, inside risk window	30	1.59	0.99-2.55	0.05
		Vaccinated with 2 nd dose, outside risk window	168	1.08	0.77-1.52	0.66
Facial nerve palsy	28 days	Total	91			
		Unvaccinated (ref.)	34	1		
		Vaccinated with 1 st dose, inside risk window	< 5	0.89	0.27-2.96	0.85
		Vaccinated with 1st dose, outside risk window	20	0.96	0.37-2.48	0.93
		Vaccinated with 2 nd dose, inside risk window	< 5	0.64	0.13-3.04	0.57
		Vaccinated with 2 nd dose, outside risk window	31	1.11	0.49-2.52	0.81
Guillain-Barré syndrome	42 days	Total	6			
		Unvaccinated (ref.)	0	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	< 5	ND	ND	ND
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	< 5	ND	ND	ND

Henoch-Schönlein purpura	42 days	Total	< 17			
		Unvaccinated (ref.)	< 5	1		
		Vaccinated with 1 st dose, inside risk window	0	ND	ND	ND
		Vaccinated with 1 st dose, outside risk window	7	0.63	0.07-5.44	0.67
		Vaccinated with 2 nd dose, inside risk window	0	ND	ND	ND
		Vaccinated with 2 nd dose, outside risk window	5	1.48	0.12-18.91	0.76
Herpes zoster	28 days	Total	80			
		Unvaccinated (ref.)	18	1		
		Vaccinated with 1st dose, inside risk window	< 5	1.56	0.25-9.67	0.63
		Vaccinated with 1 st dose, outside risk window	29	2.26	0.56-9.19	0.25
		Vaccinated with 2 nd dose, inside risk window	< 5	1.65	0.16-16.80	0.67
		Vaccinated with 2 nd dose, outside risk window	30	4.12	1.10-15.4	0.04
Idiopathic thrombocytopenic	28 days	Total	24			
purpura		Unvaccinated (ref.)	6	1		
		Vaccinated with 1 st dose, inside risk window	< 5	0.75	0.18-10.66	0.75
		Vaccinated with 1st dose, outside risk window	8	0.89	0.12-6.78	0.91
		Vaccinated with 2 nd dose, inside risk window	< 5	1.21	0.10-13.89	0.88
		Vaccinated with 2 nd dose, outside risk window	7	1.09	0.19-6.41	0.92
Lymphadenopathy	14 days	Total	651			
		Unvaccinated (ref.)	152	1		
		Vaccinated with 1 st dose, inside risk window	15	0.79	0.45-1.40	0.43
		Vaccinated with 1st dose, outside risk window	249	1.00	0.73-1.38	0.98
		Vaccinated with 2 nd dose, inside risk window	22	2.04	1.24-3.35	0.01
		Vaccinated with 2 nd dose, outside risk window	213	1.08	0.80-1.47	0.61
Multisystem inflammatory	42 days	Total	21			
syndrome in children		Unvaccinated (ref.)	6	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.14	0.17-7.52	0.89
		Vaccinated with 1 st dose, outside risk window	8	0.47	0.09-2.62	0.39
		Vaccinated with 2 nd dose, inside risk window	0	NA	NA	NA
		Vaccinated with 2 nd dose, outside risk window	< 5	1.33	0.11-16.65	0.82
Myocarditis and pericarditis	28 days	Total	< 68			
·	•	Unvaccinated (ref.)	13	1		
		Vaccinated with 1 st dose, inside risk window	< 5	1.20	0.30-4.84	0.80

		Vaccinated with 1 st dose, outside risk window	17	1.60	0.53-4.84	0.40
		Vaccinated with 2 nd dose, inside risk window	11	5.88	2.11-16.40	< 0.001
		Vaccinated with 2 nd dose, outside risk window	22	1.14	0.45-2.93	0.78
Venous thromboembolic events	28 days	Total	< 71			
		Unvaccinated (ref.)	11	1		
		Vaccinated with 1 st dose, inside risk window	5	1.05	0.35-3.16	0.93
		Vaccinated with 1 st dose, outside risk window	20	1.04	0.42-2.62	0.93
		Vaccinated with 2 nd dose, inside risk window	< 5	0.81	0.22-3.02	0.75
		Vaccinated with 2 nd dose, outside risk window	30	0.98	0.45-2.14	0.95

¹Adjustment for seasonality, defined as quarterly time periods (January–March, April–June, July–September, and October–December)